Table 2. Clinical activity of vaccine therapies in lung cancer.
| Agent | Trial phase and disease stage | Number of patients | Results |
|---|---|---|---|
| Antigen specific immunotherapy | |||
| MAGE-A3 | Phase II, IB-II NSCLC | 182 | Trend in improved DFI (HR, 0.75; P=0.254) |
| Phase III, IA-IIIA NSCLC | Ongoing | ||
| Liposomal BLP-25 | Phase II, IIIB-IV NSCLC | 171 | No OS benefit (HR, 0.739; P=0.112). Patients with stage IIIB disease had 3-year survival of 49% with vaccination vs. 27% with BSC (P=0.070) |
| Phase III, III NSCLC | 1,239 | No OS (HR, 0.88, P=0.123). Patients treated with concurrent CRT had prolonged OS (HR, 0.78; P=0.016) with vaccination | |
| TG4010 | Phase II, IIIB-IV NSCLC | 148 | 6-month PFS 43.2% with vaccination vs. 35.1% with chemotherapy alone (P=0.307) |
| rHU-EGF | Phase II, IIB-IV NSCLC | 80 | OS was 11.7 months in GAR patients vs. 3.6 months in PAR patients |
| BEC2/BCG | Phase III, limited SCLC | 515 | OS was 16.4 vs. 14.3 months (P=0.28) |
| Tumor cell vaccines | |||
| Belagenpumatucel-L | Phase II, II-IV NSCLC | 75 | OS of 14.5 months. OS in stage IIIB/IV patients with stable disease after chemotherapy was 44.4 months |
| Tergenpumatucel-L | Phase II, IV NSCLC | 28 | OS was 11.3 months |
Abbreviations: OS, overall survival; PFS, progression free survival; DFI, disease free interval; HR, hazard ratio; BSC, best supportive care; CRT, chemoradiotherapy; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; GAR, good antibody response; PAR, poor antibody response.